logo
  

Burberry Q3 Comparable Store Sales Up 1%

Burberry Group PLC (BRBY.L) reported that its third quarter comparable store sales increased 1% impacted by COVID-19-related disruption in Mainland China. Excluding Mainland China, comparable store sales grew 11%.

Quarterly comparable store sales in EMEIA region grew 19%, while it was down 1% in Americas.

Comparable store sales in Asia Pacific fell 7% with Mainland China down 23%. Declines in Mainland China were partially offset by strong performances in South Korea up 10%, Japan up 28% and SAP up 15%.

Looking ahead, the company said its near and medium-term targets remain unchanged as it continues to target high-single digit revenue growth with operating leverage ensuring good margin progression, notwithstanding the current macro environment.

Based on the effective foreign exchange rates as of 30th December 2022, Burberry Group expects a currency tailwind of about 160 million pounds on revenue and about 70 million pounds on adjusted operating profit in fiscal year 2023.

The company noted that roll out of the new store concept continued with 15 stores completed in the quarter including Pacific Place in Hong Kong S.A.R, China and North Park Centre Dallas, USA leading to 37 for the year to date and 84 stores in the new concept in total.

The company said it remains on track to complete 65 stores in fiscal year 2023 with aim to complete the roll out of the portfolio by fiscal year 2026.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
RELATED NEWS
Follow RTT